Single-cell study provides valuable resource to identify new immunotherapy strategies

Immunotherapy + radiation show promise for bladder preservation in localized MIBC, phase II study shows

Patients with localized muscle-invasive bladder cancer who received radiation plus the immune checkpoint inhibitors durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical study published in Clinical Cancer Research, a journal of the AACR.

CAR T therapy shows durable responses in large B-cell lymphoma

Allogene Therapeutics Inc. announced the publication of data from its phase I ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory large B-cell lymphoma as a rapid communication in the Journal of Clinical Oncology.

New biomarker can predict cancer aggressiveness, study finds

Researchers from Fred Hutch Cancer Center and the University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers using a new technology and computational method.

Scientists identify dysfunctional B cells as a new cancer immunotherapy target

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood—known as the tertiary lymphoid structure—where they become dysfunctional when in close contact with tumors.